Choose a country and language

EN Flag United States
GB Flag United Kingdom
NL Flag Netherlands
DE Flag Germany
NO Flag Norway
EN Flag Sweden
For all other countries, please click here.
Patients & Caregivers Healthcare Providers

Sign In

Forgot Your Password?

Sign Up

If you don't have an account, click below to Create an Account.

Create an Account

The nerve to expect more. The nerve to redefine patient expectations.

The VNS Therapy® System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications

The nerve to expect more. The nerve to redefine patient expectations.

Addressing the risks of uncontrolled seizures requires a proactive treatment strategy

Children with drug-resistant epilepsy (DRE) who are treated with anti-seizure medications (ASMs) alone could suffer from developmental deterioration that impacts motor and social function

Children with drug-resistant epilepsy (DRE) who are treated with anti-seizure medications (ASMs) alone could suffer from developmental deterioration that impacts motor and social function1

Pediatric patients who did not achieve seizure freedom for 5 continuous years were at a 5.2× greater risk of SUDEP (95% CI 1.4-18.5)

Pediatric patients who did not achieve seizure freedom for 5 continuous years were at a 5.2× greater risk of SUDEP (95% CI 1.4-18.5)2

SUDEP=sudden unexpected death in epilepsy

Poorly controlled seizures have serious cognitive consequences in the developing brain (N=198, P<0.0001)

Poorly controlled seizures have serious cognitive consequences in the developing brain (N=198, P<0.0001)3

The nerve to enable pediatric patients to overcome seizures

Early use of VNS Therapy® can help improve long-term outcomes at a critical time in a patient’s development.

Patients treated earlier in their disease were nearly 3× more likely to be seizure-free compared to those patients who delayed VNS Therapy. (N=89, follow-up at 12 months).4

Pie chart showing percent of patients with ≥50% reduction in seizure frequency

VNS Therapy® reduces the frequency, duration, and severity of seizures and improves postictal recovery

In a study of 347 pediatric patients followed up for 24 months5:

  • 48% experienced shorter seizures
  • 42% experienced a reduction in seizure severity
  • 40% experienced an improvement in postictal recovery

Bar chart showing ≥50% reduction in seizure frequency with and without AutoStim

VNS Therapy® with AutoStim* can provide better seizure control

Proportion of VNS Therapy patients who experienced a ≥50% reduction
in seizure frequency9

Observational study collected data from 10 pediatric patients who underwent surgery for a VNS Therapy battery change to AutoStim between November 2015 and July 2018. Data were collected retrospectively prior to battery replacement and prospectively for 12 months after replacement.

*Only available in models 106 and 1000

 

The nerve to enhance a patient’s quality of life

Your pediatric patients with DRE deserve the opportunity to reach their developmental potential - and VNS Therapy has helped many of them do just that. VNS Therapy has shown to offer quality-of-life (QoL) benefits that can help patients overcome the obstacles they face in everyday life.

VNS Therapy® empowers patients with meaningful QoL benefits5:
1 out of 2 patients experienced an improvement in concentration and energy
2 out of 3 patients experienced an improvement in alertness

3 out of 4 patients experienced improvements in overall QoL7

Delaying implantation has shown to have significant impacts on cognitive and overall scores related to a child’s health-related quality of life.

Delaying implantation has shown to have significant impacts on cognitive and overall scores related to a child’s health-related quality of life.

Patients on VNS Therapy® experienced reductions in health-related events

3x reduction of status epilepticus in adolescents (12-17 years of age)9 (N=207, mean follow-up at 29.9 months [±9.4 months])

3x reduction of status epilepticus in adolescents (12-17 years of age)9 (N=207, mean follow-up at 29.9 months [±9.4 months])

For patients on VNS Therapy®, SUDEP rates decreased over time

32% reduction in rates of SUDEP

In a retrospective analysis, age-adjusted SUDEP rates decreased over time from years 1 to 2 (2.47/1000 person-years) to years 3 to 10 (1.68/1000 person-years).10

SUDEP=sudden unexpected death in epilepsy

The nerve to choose a treatment that won't contribute to CNS adverse effects

VNS Therapy® has proven to be a safe, well-tolerated adjunctive treatment option that can improve your patients’ seizure control without contributing to anti-seizure medication (ASM) toxicity. As an adjunctive treatment with no drug interactions, VNS Therapy may help reduce the number and dosage of ASMs in your patient's regimen.

VNS Therapy® has proven safety and tolerability

VNS Therapy® has proven safety and tolerability

The most common side effects occur only during stimulation and typically diminish over time.11,12 The most common side effect of the surgical procedure is infection.13

VNS Therapy® has no neurotoxic effects or drug interactions11,13

Access resources to support your practice and patients

Access resources to support your practice and patients

Watch real-life patient testimonials

Watch real-life patient testimonials



References: 1. Otsuki T, Kim HD, Luan G, et al. Brain Dev. 2016;38(5):449-460. 2. Sillanpää M, Shinnar S. N Engl J Med. 2010;363(26):2522-2529. 3. Berg, AT, Zelko FA, Levy, SR, et al. Neurology. 2012;79:1384- 1391. 4. Russo A, Hyslop A, Gentile V, et al. J Child Neurol. 2020;883073820974855. doi:10.1177/0883073820974855. 5. Orosz I, McCormick D, Zamponi N, et al. Epilepsia. 2014;55(10):1576-1584. 6. Lo WB, Chevill B, Philip C, et al. Childs Nerv Syst. 2020;10.1007/s00381-020-04962-3. doi:10.1007/s00381-020-04962-3. 7. Englot DJ, Hassnain KH, Rolston JD, et al. Epilepsy Behav. 2017;66:4-9. 8. Soleman J, Stein M, Knorr C, et al. Epilepsy Behav. 2018;88:139-145. 9. Helmers SL, Duh MS, Guerin A, et al. Eur J Paediatr Neurol. 2012;16(5):449-458. 10. Ryvlin P, So EL, Gordon CM, et al. Epilepsia. 2018;59(3):562-572. 11. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415 418. 12. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735. 13. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX.